Karyopharm Therapeutics Inc. (KPTI)
NASDAQ · Healthcare
Karyopharm Therapeutics Inc. Operating Income 2011–2025
Karyopharm Therapeutics Inc. annual/quarterly operating income history and growth rate from 2011 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Karyopharm Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -26.8 M, a 19.53% decrease year-over-year.
- Karyopharm Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -99.6 M, a 16.58% decrease year-over-year.
- Karyopharm Therapeutics Inc. annual operating income for 2025 was -90.7 M, a 24.06% decrease from 2024.
- Karyopharm Therapeutics Inc. annual operating income for 2024 was -119.4 M, a 7.79% decrease from 2023.
- Karyopharm Therapeutics Inc. annual operating income for 2023 was -129.5 M, a 8.90% decrease from 2022.
- Karyopharm Therapeutics Inc. annual operating income for 2022 was -142.2 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Karyopharm Therapeutics Inc. Operating Income — FAQ
Karyopharm Therapeutics Inc. (KPTI) operating income over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
What is Karyopharm Therapeutics Inc.'s operating income?
Karyopharm Therapeutics Inc. (KPTI) reported operating income of -$91M for fiscal 2025.
Where can I see KPTI's operating income history?
The chart and table above show Karyopharm Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.